The Types segment categorizes analytical approaches into four sub‑technologies: DNA methylation analysis, Histone modification analysis, Chromatin accessibility analysis, and Non‑coding RNA analysis. DNA methylation platforms, including bisulfite sequencing and array‑based methods, dominate the type landscape, generating roughly 40 % of market value due to their established clinical utility. Histone modification analysis, leveraging ChIP‑seq and mass spectrometry, accounts for about 30 %, supported by expanding research on histone code therapeutics. Chromatin accessibility techniques such as ATAC‑seq and DNase‑seq contribute 20 %, reflecting their role in mapping regulatory elements. Non‑coding RNA analysis, encompassing miRNA and lncRNA profiling, makes up the remaining 10 %, driven by emerging interest in epigenetic RNA regulators. Together, these type subcategories delineate the functional scope of the market and inform investment decisions across the epigenomics ecosystem.